Pfizer: new Emblaveo antibiotic approved in the EU
(CercleFinance.com) - Pfizer announced on Monday that the European Commission has approved the marketing of Emblaveo, its new antibiotic for the treatment of the most resistant infections.
This antibiotic targets complex intra-abdominal infections, nosocomial pneumonia such as ventilator-associated pneumonia, and urinary tract infections such as pyelonephritis. It has also been approved for the treatment of Gram-negative bacterial infections, an area where treatment options have hitherto been limited due to multi-drug resistance. Emblaveo - which was jointly developed with AbbVie - is to be marketed internationally by Pfizer, with AbbVie holding distribution rights in the USA and Canada. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
17/05/2024 09:35
Carmat16 millions d'euros levés avec succès 17/05/2024 09:28 Richemontbénéfice net annuel en forte hausse 17/05/2024 09:10 Applied Materialshausse de 5% du BPA au 2e trimestre 17/05/2024 08:55 Scorchute de 37% du résultat net trimestriel 17/05/2024 08:40 Engieléger recul de l'EBIT hors nucléaire au 1er trimestre 17/05/2024 08:18 Clarianedébut des opérations d'augmentation de capital Tous les articles sociétés |
